within Pharmacolibrary.Drugs.ATC.H;

model H04AA01_1
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 0.00022666666666666666,
    adminDuration  = 600,
    adminMass      = 1 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.00035999999999999997,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>H04AA01_1</td></tr><td>route:</td><td>intramuscular</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Glucagon is a peptide hormone produced by the alpha cells of the pancreas. It raises blood glucose levels by promoting glycogen breakdown and gluconeogenesis in the liver. It is mainly used as an emergency treatment for severe hypoglycemia and as a diagnostic aid in radiological examinations. Glucagon is approved and in clinical use.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters after intramuscular administration in healthy individuals.</p><h4>References</h4><ol><li><p>Sherr, JL, et al., &amp; Beck, RW (2016). Glucagon Nasal Powder: A Promising Alternative to Intramuscular Glucagon in Youth With Type 1 Diabetes. <i>Diabetes care</i> 39(4) 555–562. DOI:<a href=\"https://doi.org/10.2337/dc15-1606\">10.2337/dc15-1606</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/26884472/\">https://pubmed.ncbi.nlm.nih.gov/26884472</a></p></li><li><p>Pontiroli, AE, et al., &amp; Bareggi, SR (1993). Pharmacokinetics of intranasal, intramuscular and intravenous glucagon in healthy subjects and diabetic patients. <i>European journal of clinical pharmacology</i> 45(6) 555–558. DOI:<a href=\"https://doi.org/10.1007/BF00315314\">10.1007/BF00315314</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/8157042/\">https://pubmed.ncbi.nlm.nih.gov/8157042</a></p></li><li><p>Mühlhauser, I, et al., &amp; Berger, M (1985). Pharmacokinetics and bioavailability of injected glucagon: differences between intramuscular, subcutaneous, and intravenous administration. <i>Diabetes care</i> 8(1) 39–42. DOI:<a href=\"https://doi.org/10.2337/diacare.8.1.39\">10.2337/diacare.8.1.39</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/3971846/\">https://pubmed.ncbi.nlm.nih.gov/3971846</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end H04AA01_1;
